Robert Charles Breedlove - 01 May 2025 Form 3 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: Principal Accounting Officer
Signature: /s/ Robert Charles Breedlove
Issuer symbol: PHAT
Transactions as of: 01 May 2025
Net transactions value: $0
Form type: 3
Filing time: 06 May 2025, 16:59:33 UTC
Next filing: 21 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Breedlove Robert Charles	Principal Accounting Officer	C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK	/s/ Robert Charles Breedlove	06 May 2025	0002066645

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PHAT	Common Stock						50,084	01 May 2025	Direct
holding	PHAT	Common Stock						5,108	01 May 2025	By 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PHAT	Stock Option (Right to Buy)							01 May 2025	Common Stock	12,000	$15.21	Direct	F1
holding	PHAT	Stock Option (Right to Buy)							01 May 2025	Common Stock	13,500	$8.35	Direct	F2
holding	PHAT	Stock Option (Right to Buy)							01 May 2025	Common Stock	15,750	$7.60	Direct	F3
holding	PHAT	Stock Option (Right to Buy)							01 May 2025	Common Stock	15,000	$5.76	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.
F2	The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.
F3	The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.
F4	The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.